TITLE

Schering improves as Bayer files bid

AUTHOR(S)
Robinson, Simon
PUB. DATE
May 2006
SOURCE
ICIS Chemical Business;5/1/2006, Vol. 1 Issue 17, p11
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the strong results presented by Schering going into the planned takeover by Bayer. The Berlin group said growth drivers were the multiple sclerosis drug Betaferon and the oral contraceptive Yasmin. The strongest improvement was seen in gynecology and andrology. Bayer has filed the acquisition plan with the European Union, which is due to make its initial decision on May 24, 2006.
ACCESSION #
20864653

 

Related Articles

  • Too little, too late? Abbot, Alison // Nature;3/30/2006, Vol. 440 Issue 7084, p603 

    The article examines the merger activity in the pharmaceutical industry in Germany. It details Bayer AG's offer to buy Schering AG. According to pharmaceutical analysts, the merger will affect mid-sized drug companies. There are three ways for these companies to respond according to a report...

  • News in brief.  // Nature Reviews Drug Discovery;Jul2006, Vol. 5 Issue 7, p530 

    The article presents news briefs related to the recent developments in the pharmaceutical industry. Merck & Co. Inc.'s cervical cancer vaccine Gardasil has successfully passed the regulatory and scientific hurdles, but other hurdles might prove to be more problematic. Studies have shown that the...

  • Pharma troubles are bitter pill. Williams, Dede // ICIS Chemical Business;3/17/2008, Vol. 273 Issue 11, p12 

    The article presents information on several problems faced by Bayer AG, a pharmaceutical firm headquartered in Leverkusen, Germany. It states that even though the firm seems to have revitalized its healthcare franchise Bayer HealthCare AG with the acquisition of pharma research firm Schering AG...

  • Bayer-Schering combo a better fit? Mirasol, Feliza // Chemical Market Reporter;4/3/2006, Vol. 269 Issue 13, p22 

    The article reports on Bayer AG's bid to take over Schering AG which is expected to result in a leading specialized global pharmaceutical entity. The acquisition could bolster Bayer's HealthCare division, particularly in the area of pharmaceutical specialty products. Bayer's bid trumped Merck...

  • Bayer Acquisition. S. H. // Pharmaceutical Executive;May2006, Vol. 26 Issue 5, p26 

    The article reports that Bayer will acquire Schering AG, a German pharmaceutical company. According to the article, the acquisition deal which is estimated to be worth $19.8 billion, was a response to a hostile bid from Merck KGaA. It is expected that the merger will result in 6,000 job losses...

  • Bayer meets Schering target.  // ICIS Chemical Business;6/19/2006, Vol. 1 Issue 24, p10 

    The article reports on the success of Bayer in meeting its target of acquiring at least 75% of German pharmaceutical group Schering. At an estimated € 17bn, the Schering buy will cost Bayer € 500m more than first calculated. The last-minute reentry of German pharma and chemicals...

  • Bayer Clinches Acquisition of Schering.  // Chemical Week;6/28/2006, Vol. 168 Issue 22, p5 

    The article reports on the acquisition of Schering by Bayer as of June 28, 2006. Shareholders representing majority of Schering's equity had accepted Bayer's offer by June 20. Bayer will merge its pharmaceuticals business with Schering to form Bayer Schering Pharma in Berlin, Germany. Its...

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;Aug2006, Vol. 5 Issue 8, p3 

    The article reports on the developments in the pharmaceutical industry worldwide. Bayer AG has acquired Schering AG at approximately €17 billion. The U.S. Food & Drug Administration has approved Gardasil, a cervical cancer vaccine, from Merck & Co. Inc. Abbott Laboratories Inc. and...

  • Bayer Makes Schering Offer Official; Schering Recommends Bid.  // Chemical Week;4/26/2006, Vol. 168 Issue 14, p5 

    The article reports on the official bid price for the acquisition of Schering released by Bayer in April 2006. According to Bayer, there is approximately €3 billion in liquidity available to finance the acquisition. The acquisition would increase the sales of Bayer that were generated by...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics